Biota reports loss with silver lining
29 August, 2003 by Graeme O'NeillMelbourne-based drug-discovery company Biota Holdings Ltd (ASX:BTA) has reported a AUD$10.3 million loss for the year to June 30, but much of the loss was due to $9.8 million in expenses incurred by its new US subsidiary Biota Inc during its first full year of operation.
AGT presents new data on obesity
28 August, 2003 by Melissa TrudingerAGT Biosciences (ASX:AGT) has presented data on a new gene linked to obesity at the International Diabetes Federation Conference in Paris.
Antisense launches Phase I MS trials
28 August, 2003 by Melissa TrudingerAntisense Therapeutics has initiated its first Phase I clinical trial for antisense inhibitor ATL1102, which is being trialled as a treatment for multiple sclerosis.
Changes down on the pharm
28 August, 2003 by Graeme O'NeillThe age of molecular farming may be the salvation of many Australian farms.
Meditech results show decreasing losses
27 August, 2003 by Melissa TrudingerMeditech Research (ASX:MRL) has announced its half-year results, reporting a decreased loss of AUD$1.06 million after tax compared to the same period last year.
Prima swooped on by Peregrine
27 August, 2003 by Jeremy TorrInvestment bank Peregrine Corporate has upped its stake in Prima BioMed to around 14 per cent on the back of a AUD$7.2 million share placement of 11.62 million ordinary shares.
Investors boost Ventracor coffers by $33.5m
27 August, 2003 by Melissa TrudingerArtificial heart company Ventracor (ASX:VCR) has taken advantage of its market popularity to raise AUD$33.75 million in an unexpected placement to institutional and sophisticated investors in Australia, Europe and Asia.
Amrad posts end-of-year profit
26 August, 2003 by Melissa TrudingerIn a dramatic turnaround from last year's $14.4 million loss, Amrad (ASX:AML) has posted an inaugural after-tax profit of AUD$7.4 million for the 2002-2003 financial year, which includes $1.2 million operating profit in addition to the one-off profit realised from the sale of Amrad's Richmond property.
Metabolic brings in $12m through options
25 August, 2003 by Melissa TrudingerMetabolic Pharmaceuticals (ASX:MBP) is today heralding a recently finalised exercise of listed options had brought the company AUD$12 million.
EpiTan raises $7.4m in share placement
25 August, 2003 by Melissa TrudingerEpiTan (ASX:EPT) has raised nearly AUD$7.4 million in a share placement of 14.5 million shares priced at $0.51, providing cash reserves to see the company through to the end of 2004.
IDT posts record revenues
25 August, 2003 by Melissa TrudingerMelbourne-based drug development and manufacturing company Institute of Drug Technology Australia (ASX:IDT) has posted record revenues of AUD$25.8 million for the 2002-2003 financial year.
Benitec not likely to leave IMB: McKinley
22 August, 2003 by Jeremy TorrGene silencing specialist Benitec has denied rumours that it is to relocate from its IMB (Institute for Molecular Bioscience) base in Queensland to the US, claiming that North American media misreported the situation.
Antisense raises $5 million
22 August, 2003 by Jeremy TorrDrug discovery biotech Antisense Therapeutics (ASX:ANP) has added AUD$5 million to its coffers with the placement of 38.5 million new shares to the institutional and specialist investor market.
Norwood Abbey moves into Asia
22 August, 2003 by Jeremy TorrAs part of its strategy to move into the Asian region, Norwood Abbey has appointed a new commercial partner to market its range of laser assisted drug delivery products.
Vintage research benefits wine industry
21 August, 2003 by Graeme O'NeillOn a wall at CSIRO Plant Industry's Merbein laboratories, is an old photo-micrograph of a grapevine floral bud. Dr Nigel Steele Scott, head of Plant Industry's horticultural research laboratories in Glen Osmond, South Australia, says it's his favourite image -- a portent of a revolution in viticulture that is still having an enormous impact on the Australian wine industry today.
